Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand

AIM: Liraglutide, a once-daily subcutaneous glucagon-like peptide-1 (GLP-1) agonist, is approved for treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). For patients with established cardiovascular diseases, liraglutide has also been shown to reduce major cardiovascular even...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clinicoecon Outcomes Res
Autori principali: Deerochanawong, Chaicharn, Kosachunhanun, Natapong, Gadekar, Arvind V, Chotikanokrat, Pitthaporn, Permsuwan, Unchalee
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove 2019
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6635895/
https://ncbi.nlm.nih.gov/pubmed/31372015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S201951
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi